Type 2 Diabetes and Cancer: Umbrella Review of Meta-analyses of Observational Studies
Overview
Affiliations
Objectives: To summarise the evidence and evaluate the validity of the associations between type 2 diabetes and the risk of developing or dying from cancer.
Design: An umbrella review of the evidence across meta-analyses of observational studies of type 2 diabetes with risk of developing or dying from any cancer.
Data Sources: PubMed, Embase, Cochrane database of systematic reviews, and manual screening of references.
Eligibility Criteria: Meta-analyses or systematic reviews of observational studies in humans that examined the association between type 2 diabetes and risk of developing or dying from cancer.
Results: Eligible meta-analyses assessed associations between type 2 diabetes and risk of developing cancer in 20 sites and mortality for seven cancer sites. The summary random effects estimates were significant at P=0.05 in 20 meta-analyses (74%); and all reported increased risks of developing cancer for participants with versus without diabetes. Of the 27 meta-analyses, eventually only seven (26%) compiled evidence on more than 1000 cases, had significant summary associations at P ≤ 0.001 for both random and fixed effects calculations, and had neither evidence of small study effects nor evidence for excess significance. Of those, only six (22%) did not have substantial heterogeneity (I(2)>75%), pertaining to associations between type 2 diabetes and risk of developing breast, cholangiocarcinoma (both intrahepatic and extrahepatic), colorectal, endometrial, and gallbladder cancer. The 95% prediction intervals excluded the null value for four of these associations (breast, intrahepatic cholangiocarcinoma, colorectal, and endometrial cancer).
Conclusions: Though type 2 diabetes has been extensively studied in relation to risk of developing cancer and cancer mortality and strong claims of significance exist for most of the studied associations, only a minority of these associations have robust supporting evidence without hints of bias.
Wang W, Sun P, Ren X, Lv T, Li M Health Sci Rep. 2025; 8(3):e70551.
PMID: 40066248 PMC: 11892145. DOI: 10.1002/hsr2.70551.
Cheng W, Li P, Nguyen M, Lin Y, Huang Y, Cheng T Cancer Cell Int. 2025; 25(1):79.
PMID: 40050889 PMC: 11887183. DOI: 10.1186/s12935-025-03712-2.
de Haan-Du J, Groenier K, Kleefstra N, van der Vegt B, Siesling S, Landman G BMJ Public Health. 2025; 2(1):e000050.
PMID: 40018189 PMC: 11812784. DOI: 10.1136/bmjph-2023-000050.
Wang X, Cao Y Biomolecules. 2025; 15(2).
PMID: 40001491 PMC: 11853042. DOI: 10.3390/biom15020188.
Fu R, Chen J, Fang Y, Wu Q, Zhang X, Wang Z Ther Adv Drug Saf. 2025; 16:20420986251318842.
PMID: 39974280 PMC: 11837066. DOI: 10.1177/20420986251318842.